Sequential Use of Prednisolone and Cyclosporine Is Effective in the Management of Immunotherapy-Related Hemolytic Anemia

Overview

Journal J Hematol

Specialty Hematology

Date 2024 Dec 19

PMID 39697686

Authors

Cherian Verghese

Niravkumar Brahmbhatt

Ghulam Ghous

Kapil Meleveedu

Nancy Vander Velde

Mark Hunter

Hari Parameshwaran

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (CPIs) can cause immune-related organ dysfunctions, including nephritis, pneumonitis, thyroiditis, hepatitis, colitis and more rarely hematological toxicities like immune-related autoimmune hemolytic anemia (irAIHA). Very few cases of irAIHA associated with immunotherapy have been reported, and treatment protocols remain unclear. This is partly because not all irAIHA cases are Coomb's test positive. Causes of anemia in cancer patients undergoing treatment with chemotherapy with or without immunotherapeutic agents can also be multiple. This makes it difficult to initially diagnose irAIHA, especially when CPIs are used concurrently with chemotherapy. Once alternate causes have been ruled out, a treatment plan for irAIHA is initiated based on grade of the anemia. Grade 1-2 irAIHA cases are managed with supportive interventions. However, cessation of therapy is recommended for life-threatening (grade 4) toxicity, severe (grade 3) toxicity that is recurring, or moderate (grade 2) toxicity that does not resolve with appropriate treatment for 3 months. Management of irAIHA usually involves methylprednisolone for 2 - 4 weeks with a slow taper after hemoglobin has normalized. But some cases do not respond to steroids alone and require cessation of immunotherapy or selecting alternate immunosuppressive agents. We report a protocol for treatment of grade 4 irAIHA secondary to programmed death protein 1 (PD-1) blocker pembrolizumab.

References

Davis E, Salem J, Young A, Green J, Ferrell P, Ancell K . Hematologic Complications of Immune Checkpoint Inhibitors. Oncologist. 2019; 24(5):584-588. PMC: 6516131. DOI: 10.1634/theoncologist.2018-0574. View

Xu L, Zhang T, Liu Z, Li Q, Xu Z, Ren T . Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp Hematol. 2012; 40(12):994-1004.e4. DOI: 10.1016/j.exphem.2012.08.008. View

Sun Y, Lee S, Oo T, Rojas-Hernandez C . Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases. J Immunother. 2017; 41(1):32-34. DOI: 10.1097/CJI.0000000000000194. View

Tanios G, Doley P, Munker R . Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2018; 102(2):157-162. DOI: 10.1111/ejh.13187. View

Pallet N, Fernandez-Ramos A, Loriot M . Impact of Immunosuppressive Drugs on the Metabolism of T Cells. Int Rev Cell Mol Biol. 2018; 341:169-200. DOI: 10.1016/bs.ircmb.2018.05.009. View

Barcellini W, Clerici G, Montesano R, Taioli E, Morelati F, Rebulla P . In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. Br J Haematol. 2000; 111(2):452-60. DOI: 10.1046/j.1365-2141.2000.02380.x. View

Nair R, Gheith S, Nair S . Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. N Engl J Med. 2016; 374(11):1096-7. DOI: 10.1056/NEJMc1509362. View

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

Datta S, De D . Positive direct antiglobulin tests in cancer patients on immune checkpoint inhibitors: A case series from India. Transfus Clin Biol. 2023; 30(3):341-344. DOI: 10.1016/j.tracli.2023.03.003. View

10.

Coutinho A, Chapman K . The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2010; 335(1):2-13. PMC: 3047790. DOI: 10.1016/j.mce.2010.04.005. View

11.

Bardill B, Mengis C, Tschopp M, Wuillemin W . Severe IgA-mediated auto-immune haemolytic anaemia in a 48-yr-old woman. Eur J Haematol. 2003; 70(1):60-3. DOI: 10.1034/j.1600-0609.2003.02846.x. View

12.

Johnstone P, Khan O . Pembrolizumab-associated autoimmune haemolytic anaemia. BMJ Case Rep. 2019; 12(10). PMC: 6827724. DOI: 10.1136/bcr-2018-229064. View

13.

Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature. 2011; 480(7378):480-9. PMC: 3967235. DOI: 10.1038/nature10673. View

14.

Okawa S, Kayatani H, Fujiwara K, Ozeki T, Takada K, Iwamoto Y . Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med. 2019; 58(5):699-702. PMC: 6443545. DOI: 10.2169/internalmedicine.1001-18. View

15.

Von Euw E, Chodon T, Attar N, Jalil J, Koya R, Comin-Anduix B . CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009; 7:35. PMC: 2697137. DOI: 10.1186/1479-5876-7-35. View

16.

Sun J, Schiffman J, Raghunath A, Tang D, Chen H, Sharma P . Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun. 2008; 8:9. PMC: 2935772. View

17.

Salama A, MUELLER-ECKHARDT C . Autoimmune haemolytic anaemia in childhood associated with non-complement binding IgM autoantibodies. Br J Haematol. 1987; 65(1):67-71. DOI: 10.1111/j.1365-2141.1987.tb06137.x. View